title: Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.
abstract: To identify baseline variables that predict remission according to different criteria in rheumatoid arthritis (RA) in a comprehensive French ESPOIR early arthritis database.
  
  
  
  Individual variables and indices at baseline were analyzed in 664 patients for capacity to predict remission either 6 or 12 months later according to 4 criteria that require a formal joint count: the American College of Rheumatology/European League Against Rheumatism Boolean criteria, the Simplified Disease Activity Index, the Clinical Disease Activity Index, and the 28-joint Disease Activity Score; and 2 remission criteria that do not require a formal joint count: the Routine Assessment of Patient Index Data 3 (RAPID3) and the RAPID3 ≤ 3 + swollen joint, using univariate and multivariate logistic regressions.
  
  
  
  Remission was predicted significantly 6 and/or 12 months later in 26.8%-51.4% of patients, according to all 6 criteria by younger age, low index scores, and better status for the 6/7 clinical RA core dataset measures: tender joint count, swollen joint count (SJC), physician's global estimate, patient self-report Health Assessment Questionnaire (HAQ) physical function, pain, and patient's global estimate. Remission was not predicted by the absence of "poor prognosis RA" indicators, rheumatoid factor (RF), anticitrullinated protein antibodies (ACPA), or radiographic erosions. In multivariate regressions that included only 3 variables, low HAQ function predicted remission by all criteria as effectively as SJC, erythrocyte sedimentation rate, or C-reactive protein.
  
  
  
  Younger age and 6 core dataset clinical measures, but not the absence of traditional "poor prognosis RA" indicators, RF, ACPA, or radiographic erosions, predicted remission according to 6 criteria, including 2 without a formal joint count.
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center.
authors.forename: Isabel
authors.initials: I
authors.lastname: Castrejón
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center.
authors.forename: Maxime
authors.initials: M
authors.lastname: Dougados
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center.
authors.forename: Bernard
authors.initials: B
authors.lastname: Combe
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center.
authors.forename: Bruno
authors.initials: B
authors.lastname: Fautrel
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center.
authors.forename: Francis
authors.initials: F
authors.lastname: Guillemin
authors.affiliation: From the Division of Rheumatology, Rush University Medical Center, Chicago, Illinois, USA; Paris Descartes University; Department of Rheumatology, Hôpital Cochin; Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Pitie-Salpetriere University Hospital, Paris; Department of Rheumatology, CHU Lapeyronie, Montpellier University, Montpellier; University of Lorraine, EA 4360 APEMAC, Nancy, France.I. Castrejón, MD, PhD, Division of Rheumatology, Rush University Medical Center; M. Dougados, MD, PhD, Paris Descartes University, and Department of Rheumatology, Hôpital Cochin, and Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; B. Combe, MD, PhD, Department of Rheumatology, CHU Lapeyronie, Montpellier University; B. Fautrel, MD, PhD, APHP, Pitie-Salpetriere University Hospital; F. Guillemin, MD, PhD, University of Lorraine, EA 4360 APEMAC; T. Pincus, MD, Division of Rheumatology, Rush University Medical Center. tedpincus@gmail.com.
authors.forename: Theodore
authors.initials: T
authors.lastname: Pincus
mesh_terms: D000328:Adult; D000075422:Anti-Citrullinated Protein Antibodies / Q000097:blood*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D016208:Databases, Factual; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D005602:France; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012217:Rheumatoid Factor / Q000097:blood*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000075422:Anti-Citrullinated Protein Antibodies; D018501:Antirheumatic Agents; D012217:Rheumatoid Factor
keywords: ESPOIR; RAPID3; REMISSION CRITERIA; RHEUMATOID ARTHRITIS